MDT

89.73

+0.54%↑

VEEV

282.11

+0.97%↑

A

113.48

+0.27%↑

WBA

11.52

+0.09%↑

HQY

97.58

+1.43%↑

MDT

89.73

+0.54%↑

VEEV

282.11

+0.97%↑

A

113.48

+0.27%↑

WBA

11.52

+0.09%↑

HQY

97.58

+1.43%↑

MDT

89.73

+0.54%↑

VEEV

282.11

+0.97%↑

A

113.48

+0.27%↑

WBA

11.52

+0.09%↑

HQY

97.58

+1.43%↑

MDT

89.73

+0.54%↑

VEEV

282.11

+0.97%↑

A

113.48

+0.27%↑

WBA

11.52

+0.09%↑

HQY

97.58

+1.43%↑

MDT

89.73

+0.54%↑

VEEV

282.11

+0.97%↑

A

113.48

+0.27%↑

WBA

11.52

+0.09%↑

HQY

97.58

+1.43%↑

Search

Recursion Pharmaceuticals Inc

Chiusa

SettoreSettore sanitario

5.38 3.07

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

5.21

Massimo

5.53

Metriche Chiave

By Trading Economics

Entrata

-24M

-202M

Vendite

10M

15M

Margine di Profitto

-1,373.259

Dipendenti

800

EBITDA

-26M

-191M

Raccomandazioni

By TipRanks

Raccomandazioni

Neutrale

Previsioni per 12 mesi

+18.37% upside

Dividendi

By Dow Jones

Utili prossimi

7 ago 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

-27M

2.3B

Apertura precedente

2.31

Chiusura precedente

5.38

Notizie sul Sentiment di mercato

By Acuity

67%

33%

327 / 376 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Very Strong Bearish Evidence

Recursion Pharmaceuticals Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

16 lug 2025, 23:56 UTC

Acquisizioni, Fusioni, Takeovers

Alimentation Couche-Tard Ends Bid to Buy Seven & I Holdings -- 2nd Update

16 lug 2025, 23:43 UTC

Acquisizioni, Fusioni, Takeovers

Santos 2Q Output Rises 1% as Takeover Campaign Continues

16 lug 2025, 23:00 UTC

Acquisizioni, Fusioni, Takeovers

Alimentation Couche-Tard Ends Bid to Buy Seven & I Holdings -- Update

16 lug 2025, 22:38 UTC

Acquisizioni, Fusioni, Takeovers

Alimentation Couche-Tard Withdraws Seven & i Acquisition Proposal

16 lug 2025, 23:44 UTC

Discorsi di Mercato

Gold Steady; Geopolitical Tensions in Middle East Support -- Market Talk

16 lug 2025, 23:42 UTC

Discorsi di Mercato

Nikkei May Fall as Yen Strengthens -- Market Talk

16 lug 2025, 23:24 UTC

Discorsi di Mercato

Australian Job Market Data to Shape RBA Calls -- Market Talk

16 lug 2025, 23:18 UTC

Acquisizioni, Fusioni, Takeovers

Santos Now Expects 2025 Production of 90 Million-95 Million BOE

16 lug 2025, 23:18 UTC

Acquisizioni, Fusioni, Takeovers

Santos Cuts Top End of 2025 Production Guidance

16 lug 2025, 23:17 UTC

Acquisizioni, Fusioni, Takeovers

Santos: Production Recovery Underway in Cooper Basin

16 lug 2025, 23:17 UTC

Acquisizioni, Fusioni, Takeovers

Santos: Over 200 Wells, Several Upstream Compressors in Cooper Basin Shut In

16 lug 2025, 23:17 UTC

Acquisizioni, Fusioni, Takeovers

Santos: Cooper Basin Production Impacted by Floods in 2Q

16 lug 2025, 23:16 UTC

Acquisizioni, Fusioni, Takeovers

Santos: Pikka Phase 1 Project in Alasia 89% Complete

16 lug 2025, 23:16 UTC

Acquisizioni, Fusioni, Takeovers

Santos Keeps 2025 Major Development Project Capex Guidance Unchanged

16 lug 2025, 23:13 UTC

Acquisizioni, Fusioni, Takeovers

Santos Had Gearing of 20.5% at End-June, Excluding Operating Leases

16 lug 2025, 23:13 UTC

Acquisizioni, Fusioni, Takeovers

Santos Says Moomba CCS Phase 1 Project Performing to Expectations

16 lug 2025, 23:12 UTC

Acquisizioni, Fusioni, Takeovers

Santos Narrows 2025 Unit Production Cost Guidance to US$7.00-US$7.40/BOE

16 lug 2025, 23:12 UTC

Acquisizioni, Fusioni, Takeovers

Santos 1H Free Cash Flow From Operations US$1.1 Billion

16 lug 2025, 23:11 UTC

Acquisizioni, Fusioni, Takeovers

Santos 2Q Free Cash Flow From Operations US$620 Million

16 lug 2025, 23:11 UTC

Acquisizioni, Fusioni, Takeovers

Santos 2Q Oil, Natural Gas Output 22.2 Million BOE

16 lug 2025, 23:11 UTC

Acquisizioni, Fusioni, Takeovers

Santos 2Q Oil, Natural Gas Sales Volumes 23.9 Million BOE

16 lug 2025, 23:11 UTC

Acquisizioni, Fusioni, Takeovers

Santos 2Q Oil, Natural Gas Sales Volumes Up 3% on 1Q

16 lug 2025, 23:11 UTC

Acquisizioni, Fusioni, Takeovers

Santos 2Q Oil, Natural Gas Output Up 1% on 1Q

16 lug 2025, 22:43 UTC

Discorsi di Mercato

Alcoa Using High Costs of More Production to Battle Tariff -- Market Talk

16 lug 2025, 22:35 UTC

Discorsi di Mercato
Utili

Global Equities Roundup: Market Talk

16 lug 2025, 22:35 UTC

Discorsi di Mercato
Utili

Replacing Aluminum Imports With U.S. Production Not Seen Feasible -- Market Talk

16 lug 2025, 22:33 UTC

Discorsi di Mercato
Utili

Alcoa Will Continue to Ship Aluminum Outside of the U.S. -- Market Talk

16 lug 2025, 22:28 UTC

Discorsi di Mercato
Utili

Aluminum Price in U.S. Doesn't Offset Tariff Costs, Alcoa says -- Market Talk

16 lug 2025, 22:22 UTC

Discorsi di Mercato
Utili

Market Talk Roundup: Latest on U.S. Politics

16 lug 2025, 22:22 UTC

Discorsi di Mercato
Utili

Alcoa Considers Restart of Idle Capacity at Indiana Smelter -- Market Talk

Confronto tra pari

Modifica del prezzo

Recursion Pharmaceuticals Inc Previsione

Obiettivo di Prezzo

By TipRanks

18.37% in crescita

Previsioni per 12 mesi

Media 6.25 USD  18.37%

Alto 8 USD

Basso 4 USD

Basato su 5 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Recursion Pharmaceuticals Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Neutrale

5 ratings

1

Acquista

4

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

4.15 / 4.75Supporto e resistenza

A breve termine

Very Strong Bearish Evidence

A termine intermedio

Bearish Evidence

A lungo termine

Bearish Evidence

Sentiment

By Acuity

327 / 376 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Prove ribassiste

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Recursion Pharmaceuticals Inc

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.